New research clarifies terminology used for diagnosis, but questions remain around epidemiology, genetics and management of patients with axial skeletal inflammation
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
Why Antiphospholipid Antibody Syndrome Should Be On Your Radar
With a wide range of clinical manifestations and frequent occurrence among rheumatology patients, APS is one for rheumatologists to watch
Childhood-onset Lupus Brings Distinct Challenges at Each Phase of Life
Differences in disease manifestations, severity, and management require special consideration from rheumatologists who treat children and adolescents with systemic lupus erythematosus
ACR/ARHP Annual Meeting 2012: Cyclophosphamide and Rituximab Both Viable Treatment Options for ANCA-Associated Vasculitis
Rituximab established as the drug of choice in patients with severe disease relapse, though cyclophosphamide may still play an important role for some patients, say rheumatologists
Maintenance of Remission in ANCA-Associated Vasculitis
Relapses are common, but difficult to predict and prevent.
Drug Updates: Lorcaserin, Acetaminophen, and More
information on new approvals and medication safety
Inflammatory Myopathies in Children
Treatment options and recent research for juvenile dermatomyositis.
Drug Updates
Information on new approvals and medication safety.
Clinical Opportunities at the 2012 ACR/ARHP Annual Meeting
The Annual Meeting will provide numerous opportunities to learn the latest clinical findings in the field and to update their knowledge in all aspects of rheumatology.
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- Next Page »